Postoperative radiotherapy in prostate cancer: Acquired certainties and still open issues. A review of recent literature

Tumori

Volumn 97, Issue 1, 2011, Pages 1-8

  Alongi, Filippo ^a   Cozzarini, Cesare ^b   Di Muzio, Nadia ^b   Scorsetti, Marta ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Postoperative radiotherapy; Prostate cancer; Radical prostatectomy

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

ANTIANDROGEN THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; OVERALL SURVIVAL; PRESCRIPTION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; RADICAL RETROPUBIC PROSTATECTOMY; REVIEW; SALVAGE RADIOTHERAPY; SALVAGE THERAPY; UROGENITAL TRACT DISEASE;

HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PATIENT SELECTION; PELVIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 79953867351     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/611.7129     Document Type: Review

References (43)

1. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol, 167: 528-534, 2002. (Pubitemid 34074521)
2. Bolla M, van Poppel H, Collette L: Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet, 366: 572-578, 2005.
3. Johnson EK, Wood DP Jr: Converting from open to robotic prostatectomy: key concepts. Urol Oncol, 281: 77-80, 2010.
4. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby- Hagino E, Crawford ED: Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA, 296: 2329-2335, 2006. (Pubitemid 44749360)
5. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K: Phase III results of adjuvant radiotherapy (RT) versus "wait and see" in patients with pT3 prostate cancer following radical prostatectomy (RP),(ARO 96-02/AUO AP 09/95). J Clin Oncol, 23: 4513, 2005.
6. Thompson IA, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby- Hagino E, Crawford ED: Adjuvant radiotherapy for pathological t3n0m0 prostate cancer significantly reduces risk of metastases and improves survival: long-termfollow up of a randomized clinical trial. J Urol, 181: 956-962, 2009.
7. Swanson P, Thompson IM: Adjuvant radiotherapy for high-risk patients following radical prostatectomy. Urol Oncol, 25: 515-519, 2007.
8. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED: Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol, 25: 2225-2229, 2007. (Pubitemid 46954647)
9. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol, 172: 910-914, 2004. (Pubitemid 39096421)
10. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, Bosset JF, Kurth KH, Schröder FH, Collette L: Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol, 25: 4178-4186, 2007. (Pubitemid 47548556)
11. Pasquier D, Ballereau C: Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review. Int J Radiat Oncol Biol Phys, 72: 972-979, 2008.
12. Jereczek-Fossa BA, Zerini D, Vavassori A, Fodor C, Santoro L, Minissale A, Cambria R, Cattani F, Garibaldi C, Serafini F, Matei VD, de Cobelli O, Orecchia R: Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy. Int J Radiat Oncol Biol Phys, 74: 115-125, 2009.
13. Choo R, Hruby G, Hong J, Bahk E, Hong E, Danjoux C, Morton G, DeBoer G: (IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int J Radiat Oncol Biol Phys, 53: 269-276, 2002. (Pubitemid 34522092)
14. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA, 291: 1325-1332, 2004. (Pubitemid 38541647)
15. Macdonald OK, Schild SE, Vora SA, Andrews PE, Ferrigni RG, Novicki DE, Swanson SK, Wong WW: Salvage radiotherapy for palpable, locally recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys, 58: 1530-1535, 2004. (Pubitemid 38438317)
16. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol, 165: 1146-1151, 2001.
17. Freedland SJ, Sutter ME, Dorey F, Aronson WJ: Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology, 61: 365-369, 2003.
18. Scattoni V, Montorsi F, Picchio M, Roscigno M, Salonia A, Rigatti P, Fazio F: Diagnosis of local recurrence after radical prostatectomy. BJU Int, 93: 680-688, 2004. (Pubitemid 38375788)
19. Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, Mancini M: Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med, 113: 895-904, 2008.
20. 11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging, 37: 301-309, 2010.
21. Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR: Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol, 166: 111-115, 2001.
22. Roscigno M, Cozzarini C, Scattoni V, Bertini R, Da Pozzo L, Pasta A, Montorsi F, Bolognesi A, Fiorino C, Colombo R, Fazio F, Rigatti P: A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy. Radiother Oncol, 82: 30-37, 2007. (Pubitemid 46110914)
23. Anscher MS: Salvage radiotherapy for recurrent prostate cancer: the earlier the better. JAMA, 291: 1380-1382, 2004.
24. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A: Long-termresults of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys, 70: 67-74, 2008.
25. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys, 41: 491-500, 1998. (Pubitemid 28275076)
26. Valicenti RK, Gomella LG, Ismail M, Mulholland SG, Petersen RO, Corn BW: Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Int J Radiat Oncol Biol Phys, 42: 501-506, 1998. (Pubitemid 28501097)
27. Valicenti RK, Gomella LG, Ismail M, Mulholland SG, Strup S, Petersen RO, Corn BW, Lu JD: Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose. Urology, 52: 1034-1040, 1998. (Pubitemid 28533373)
28. Cozzarini C, Fiorino C, Montorsi F, Alongi F, Da Pozzo LF, Bolognesi A, Da Pozzo LF, Guazzoni G, Freschi M, Roscigno M, Scattoni V, Rigatti P, DiMuzio N: The need for high radiation doses (≥70 Gy) in early post-operative irradiation after radical prostatectomy. Amono institutional analysis on 334 consecutive high risk patients. Int J Radiat Oncol Biol Phys, 75: 966-974, 2009.
29. King CR, Kapp DS: Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys, 71: 346-350, 2008.
30. Zelefsky MJ, Aschkenasy E, Kelsen S, Leibel SA: Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys, 39: 327-333,1997.
31. Fiorino C, Alongi F, Broggi S, Cattaneo M, Cozzarini C, Di Muzio N, Maggiulli E, Mangili P, Perna L, Valdagni R, Fazio F, Calandrino R: Physics aspects of prostate tomotherapy: planning optimization and image-guided issues. Acta Oncol, 47: 1309-1316, 2008.
32. Alongi F, Fiorino C, Cozzarini C, Broggi S, Perna L, Cattaneo GM, Calandrino R, DiMuzio N: IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol, 93: 207-212, 2009.
33. Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, Boehmer D, Budiharto T, Symon Z, van den Bergh AC, Scrase C, Van Poppel H, Bolla M, EORTC Radiation Oncology Group: Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiat Oncol, 84: 121-127, 2007. (Pubitemid 47284534)
34. Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Ménard C: Development of RTOG Consensus Guidelines for the Definition of the Clinical Target Volume for Postoperative Conformal Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys, 76: 361-368, 2010.
35. Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS, Radiation Therapy Oncology Group 9413: Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression. J Clin Oncol, 21: 1904-1911, 2003.
36. Heidenreich A, Varga Z, Von Knobloch R: Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol, 167: 1681-1686, 2002. (Pubitemid 34240702)
37. Cozzarini C, Fiorino C, Di Muzio N, Alongi F, Broggi S, Cattaneo M, Montorsi F, Rigatti P, Calandrino R, Fazio F: Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer. Radiother Oncol, 84: 164-170, 2007. (Pubitemid 47299141)
38. Da Pozzo LF, Cozzarini C, Briganti A, Suardi N, Salonia A, Bertini R, Gallina A, Bianchi M, Fantini GV, Bolognesi A, Fazio F, Montorsi F, Rigatti P: Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol, 55: 1003-1011, 2009.
39. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L, EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med, 360: 2516-2527, 2009.
40. D'Amico AV, Manola J, Loffredo M, Loffredo M, Renshaw AA, Della Croce A, Kantoff PW: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA, 292: 821-827, 2004. (Pubitemid 39079668)
41. Lee AK: Radiation therapy combined with hormone therapy for prostate cancer. Semin Radiat Oncol, 16: 20-28, 2006.
42. Eulau SM, Tate DJ, Stamey TA, Bagshaw MA, Hancock SL: Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys, 41: 735-740, 1998. (Pubitemid 28285948)
43. King CR, Presti JCJ, Gill H, Brooks J, Hancock SL: Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys, 59: 341-347, 2004.